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INTRODUCTION AND OBJECTIVES: Tuberculosis and cancer are the main causes of pleural effusion. Pleural involvement 
is associated with migration of immune cells to the pleural cavity. We sought to characterize the immunophenotype of leukocytes 
in the pleural effusion and peripheral blood of patients with tuberculosis or malignancy.
METHODS: Thirty patients with tuberculosis (14) or malignancy (16) were studied. A control group included 20 healthy blood 
donors.
RESULTS: Malignant phycoerythrin pleural effusions showed higher percentages of CD3, CD4, CD3CD45RO, and CD20CD25 
lymphocytes and lower percentages of CD3CD25 and CD20HLA-DR when compared to PB lymphocytes. Compared to PB, tu-
berculous effusions had a higher percentage of lymphocytes that co-expressed CD3, CD4, CD3CD45RO, CD3TCRαβ, CD3CD28, 
and CD20 and a lower percentage of CD14, CD8 and CD3TCRγδ-positive lymphocytes. Malignant effusions presented higher 
expression of CD14 whereas tuberculous effusions had higher expression of CD3 and CD3CD95L. Peripheral blood cells from 
tuberculosis patients showed higher expression of CD14, CD20CD25 and CD3CD95L. Compared with the control cells, tubercu-
losis and cancer peripheral blood cells presented a lower percentage of CD3CD4 and CD3CD28-positive cells as well as a higher 
percentage of CD3CD8, CD3CD25 and CD3CD80-positive cells.
CONCLUSIONS: Tuberculous and malignant peripheral blood is enriched with lymphocytes with a helper/inducer T cell phenotype, 
which are mainly of memory cells. CD14-positive cells were more frequently found in malignant effusions, while CD3-positive 
cells expressing Fas ligand were more frequently found in tuberculous effusions.
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INTRODUCTION
The accumulation of fluid in the pleural space indicates 
the presence of systemic or local disease. Pleural exudates 
involve the migration of immune cells to the pleural 
cavity.1 Characterization of the cellular composition 
of such exudates may provide insight into the relevant 
pathophysiological mechanisms and the functional state 
of the cells. Tuberculosis and cancer represent the main 
causes of pleural exudates. In both cases, the pleural 
fluid is generally lymphocytic, with a predominance of T 
lymphocytes, particularly CD4-positive T cells.2
Considering the compartmentalization of the pleural 
space, the association between the local and systemic cellular 
responses should be analyzed. Some investigators have 
found that, when compared with peripheral blood, exudates 
have increased numbers of CD4-positive T lymphocytes. 
However, the immunophenotypic profile of the pleural fluid 
does not permit discrimination of the causal diagnosis.2-7
Different cell populations have been described in 
tuberculous fluid. Kapila et al.8 reported a predominance of 
CD4- positive T lymphocytes with a CD4/CD29 phenotypic 638
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profile when compared to blood, suggesting that these cells 
represent memory T cells.9,10 On the other hand, Dlugovitzky 
et al.11 reported an increase in the number of CD25-positive 
cells (IL-2 receptor-expressing), whereas Faith et al.12 
observed expression of the HLA-DR marker, suggesting the 
presence of activated T cells.
Similarly, several studies have evaluated the lymphocytic 
profile (pleural fluid and blood) of patients with cancer. 
These studies generally indicate a predominance of T 
lymphocytes in the pleural fluid, with increased prevalence 
of a CD4-positive subpopulation when compared to 
blood13-17. Baxevanis et al.18 and Mantovani et al.19 
demonstrated a lower percentage of natural killer cells 
(CD16) in the pleural fluid than in peripheral blood. Only a 
minority of T lymphocytes were activated, which expressed 
CD38 and HLA-DR surface markers.14 These lymphocytes 
were found to have natural killer activity and very low 
antitumor cytotoxicity, which is suggestive of depressed 
immune function15. Another factor associated with the lack 
of a T cell-mediated immune response is the existence of 
an apoptotic mechanism that, in addition to regulating the 
homeostasis of cell populations, acts to eliminate self-
reactive lymphocytes and negatively regulate the immune 
response.20-22 The apoptotic signal is transmitted to mature 
T cells through various membrane receptors, mainly 
CD3/TCR, Fas/Apo/CD95, TNF, CTL-4, and CD2. Only 
activated T cells develop the cellular substrate required for 
transmission of the apoptotic signal.23 Thus, the analysis 
of cell surface markers permits the evaluation of cellular 
differentiation (CD3, CD4, CD8, CD15, CD20, CD56, 
TCRαβ, and TCRγδ), cellular activation (CD25, CD45RA, 
CD45RO, and HLA-DR), and immune co-stimulation 
(CD28, CD80, CD86 and CD152) in pleural fluid and blood. 
The aim of this study was to elucidate the pathophysiological 
mechanisms involved in the genesis of pleural exudates of 
tuberculous or neoplastic origin.
PATIENTS AND METHODS
The Ethics Committee of our institution approved this 
study. Thirty patients with pleural exudates (14 tuberculosis, 
16 cancer) with no previous treatment were included in the 
study. These patients were indicated for thoracocentesis 
and underwent collection of pleural fluid and blood after 
they signed an informed consent form. Light’s criteria24 
were used for classification of transudate or exudate. The 
diagnosis of tuberculosis was made based on the presence 
of compatible clinical and radiological signs associated 
with a M. tuberculosis-positive culture from fluid or pleural 
fragments, on the presence of caseous granuloma in the 
pleura, or both. The presence of tumor cells in the pleural 
fluid or tissue indicated cancer.
Twenty healthy blood donors were included in the study 
as well (blood control).
Biochemical examinations and pleural fluid cytology
Biochemical examination of blood and pleural fluid 
(protein and lactate dehydrogenase) and blood count were 
performed using automatic devices (Cobas Integra 700, 
West Sussex, UK; Pentra 120, Horiba ABX, Montpellier, 
France). The total number of nucleated cells (pleural fluid) 
was quantified in a Neubauer chamber (Hausser Scientific, 
Horsham, PA). Slides stained with Leishman panoptic stain 
were used for qualitative and oncotic cytology.
Cell preparation and cell viability testing
The mononuclear cell concentrate was obtained by 
centrifugation of pleural fluid or blood (1500 rpm for 10 
min at 25oC), and the final concentration was adjusted to 2 x 
107 cells/mm2. Cell viability was evaluated by Trypan blue 
exclusion (Gibco BRL, Grand Island, NY). Only samples 
with more than 70% viable cells were used in this study. 
Flow cytometry
Blood or pleural fluid cells were incubated with mono-
clonal antibodies conjugated to fluorescein isothio  cyanate 
(FITC) or phycoerythrin (PE). Direct immunofluorescence 
was used for the analysis of cell surface antigens other than 
CD95-L. Autofluorescence of cells and nonspecific binding 
of monoclonal antibodies were corrected for by using iso-
typic controls. Antigens were quantified by the detection of 
fluorescence emitted by fluorochrome-labeled monoclonal 
antibodies in a FACSCalibur flow cytometer (Becton-Dickin-
son, San Jose, CA) using the CellQuest (Becton Dickinson) 
program.
Cell populations were identified based on analysis of 
the cytograms. Cell data were arranged in 2-dimensional 
cytograms (abscissa: cell size; ordinate: internal cell 
complexity). Leukocytes were identified by quantification 
of anti-CD45-labeled cells. Among the CD45-positive 
population, the group with the lowest internal complexity 
corresponded to lymphocytes. CD45, CD15- and CD45, 
CD14-positive cells characterized granulocytes and 
monocytes/macrophages. T, B, and natural killer lymphocytes 
were identified based on their staining by CD3, CD20, and 
CD56 antibodies.
Cell surface markers for activation, co-stimulation, and 
apoptosis co-expressed by T lymphocytes, B-lymphocytes, 
or monocytes/macrophages were quantified in cells that were 639
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positive for CD3, CD20, and CD14, respectively, on the 
abscissa with surface antigens on the ordinate.
Apoptosis
Leukocyte apoptosis was analyzed in blood and pleural 
fluid using the APO-BRDU kit (Pharmigen, San Diego, 
CA). Mononuclear cells were separated on a density 
gradient using the Lymphoprep kit (Nycomed Pharma, Oslo, 
Norway). A suspension of 2 x 106 cells in a 5-ml aliquot of 
phosphate-buffered saline was held on ice (15 min). After 
several washes, the cell sediment obtained by centrifugation 
was diluted in 50 µl of DNA strand-break labeling solution. 
Cells were then incubated with 0.1 ml of anti-BrDu (FITC) 
solution, followed by 0.5 ml PI dye/RNase A solution. 
Apoptosis was quantified based on the fluorescence emitted 
by the FITC-labeled anti-BrDu antibody in a FACSCalibur 
cytometer using the Cell Quest program (Becton-Dickinson, 
São Paulo, Brazil).
Statistical analysis
The paired t test (normal distribution) and Wilcoxon test 
(not normal distribution) were used for comparisons of blood 
and pleural fluid. Leukocyte subpopulations (fluid) were 
compared using the Student’s t test or the Mann-Whitney 
test. Differences in the blood leukocyte subpopulation 
percentage among groups were determined by analysis 
of variance (ANOVA), followed by Tukey’s multiple 
comparisons or the Kruskal-Wallis test and Dunn’s multiple 
comparison procedure. The level of significance was set at 
0.05, and SPSS 10.0 for Windows statistical software was 
used for analysis.
RESULTS
Thirty patients were studied: 14 (12 men and 2 women; 
mean age: 36.9 years) with pleural tuberculosis and 16 (5 
men and 11 women; mean age: 60.4 years) with malignant 
effusion.
Immunophenotypic profile of pleural fluid
Four main patterns of cell distribution were identified 
using 2-dimensional cytograms (abscissa: cell size; ordinate: 
internal complexity of cells):
Pattern 1: Small cells of low complexity (region usually 
occupied by lymphocytes in normal blood).
Pattern 2: Cell population described in pattern 1 plus cells 
with small size and high internal complexity (corresponding 
to granulocytes in normal blood).
Pattern 3: Populations 1 and 2, plus medium-sized and 
medium-complexity cells (corresponding to monocytes in 
normal blood).
Pattern 4: Population 1, plus cells of variable size and 
complexity (probably corresponding to macrophages and 
mesothelial cells in fluid).
Pleural fluid from patients with tuberculosis had cells 
with patterns 1 (9/14; 64.3%) and 3 (5/14; 35.7%), whereas 
most fluid secondary to cancer had cells with patterns 4 
(10/16; 62.5%) and 1 (4/16; 25.0%).
Comparison of cellular components between tuberculous 
or malignant fluid showed a significant difference in the 
percentage of T lymphocytes (CD3) and monocytes/
macrophages (CD14). Neoplastic effusions had a higher 
percentage of CD14-positive cells (monocytes/macrophages) 
than did tuberculous effusions (p = 0.006), whereas the 
percentage of CD3-positive cells (T lymphocytes) was 
higher in tuberculous effusions (p = 0.002). Although the 
Table 1 - Percentage (mean ± standard deviation) of leukocyte 
subpopulations in pleural fluid of patients with Tb or cancer 
(* p < 0.05)
Cells Tuberculous Malignant P
CD15 2.3 (2.5) 7.0 (21.7) 0.967
CD14 5.3 (3.9) 17.4 (15.0) 0.006
CD14CD86 99.0 (1.0) 81.8 (37.6) 0.867
Lymphocytes * 87.3 (9.3) 52.3 (23.7) 0.036
CD3 * 75.2 (9.0) 52.3 (23.7) 0.002
CD20 6.2 (3.1) 7.9 (6.9) 0.389
CD56 2.9 (1.4) 2.2 (1.5) 0.150
CD20HLA 99.5 (0.4) 91.5 (25.4) 0.600
CD20CD25 25.6 (17.3) 25.8 (21.3) 0.972
CD20CD80 8.4 (4.7) 15.6 (20.9) 0.570
CD20CD86 13.4 (11.5) 7.0 (8.0) 0.086
CD3CD4 73.0 (5.9) 66.6 (19.8) 0.234
CD3CD8 25.7 (5.9) 32.5 (19.4) 0.202
CD3CD4/CD3CD8 3.1 (1.1) 3.3 (2.6) 0.780
CD3TCRαβ 97.6 (1.8) 90.7 (12.9) 0..67
CD3TCRγδ 2.9 (1.7) 4.3 (3.5) 0.182
CD3CD45RA 32.1 (15.6) 23.5 (20.8) 0.214
CD3CD45RO 73.2 (11.6) 66.1 (26.8) 0.349
CD3HLA 19.7 (10.0) 19.7 (12.4) 0.999
CD3CD25 22.7 (12.6) 22.8 (15.7) 0.990
CD3CD28 88.6 (15.1) 73.0 (29.4) 0.076
CD3CD80 1.5 (1.3) 2.5 (2.3) 0.160
CD3CD95 79.7 (14.1) 66.2 (33.9) 0.162
CD3CD95L 55.7 (41.0) 26.5 (26.5) 0.061
CD3CD152 1.6 (1.3) 2.1 (1.5) 0.421640
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percentage of pro-apoptotic T lymphocytes (CD3, CD95L+) 
appeared to be higher in tuberculous effusions, the statistical 
significance was marginal (p = 0.061) (Table 1).
Comparison of cells in pleural fluid and blood
The following cell populations were found to be elevated 
in tuberculous effusions: total lymphocytes (p < 0.001), 
TCD3 (p < 0.001), CD3CD4 (p < 0.001), CD3CD45RO (p 
= 0.001), CD3TCRαβ (p = 0.009), CD3CD28 (p = 0.003), 
and CD20 (p < 0.001). The CD4/CD8 ratio was also higher 
in pleural fluid (p < 0.001) (Table 2). In malignancy, a higher 
percentage of the following cell types and subtypes were 
observed in the pleural fluid: total lymphocytes (p < 0.001), 
CD3 lymphocytes (p < 0.001), CD3CD4 lymphocytes (p = 
0.001), CD3CD45RO lymphocytes (p = 0.002), CD20CD25 
lymphocytes (p = 0.006), and CD3TCRαβ lymphocytes (p 
= 0.028). The CD4/CD8 ratio was also higher in the pleural 
fluid (p = 0.039) (Table 3).
These results demonstrate that lymphocytes represent the 
predominant cell population in malignant effusions and that 
these lymphocytes are mainly helper/inducer T cells (CD4) 
with a memory cell phenotype (CD45RO). The same profile 
was observed in effusions from patients with tuberculosis.
Comparison of cells in peripheral blood: tuberculosis 
versus cancer
No significant differences were observed for most surface 
markers. However, a higher percentage of CD14 (p = 0.012), 
CD3CD95L (p = 0.005), and CD20CD25 cells (p = 0.006) 
were observed in the tuberculosis group (Table 4).
When we compared blood cell subpopulations between 
patients with tuberculosis or cancer and the control group, 
Table 2 - Percentage (mean ± standard deviation) of leuko-
cyte subpopulations in peripheral blood and pleural fluid of 
patients with tuberculous pleural effusions (* p < 0.05)
Cells Pleural fluid Blood P
CD15 * 2.3 (2.5) 62.4 (8.0) 0.000
CD14 * 5.3 (3.9) 10.7 (3.0) 0.003
CD14CD86 99.0 (1.0) 99.3 (0.8) 0.236
Lymphocytes * 87.3 (9.3) 23.1 (6.8) 0.000
CD3 * 75.2 (9.0) 13.9 (4.6) 0.000
CD20 * 6.2 (3.1) 2.0 (1.0) 0.000
CD56 2.9 (1.3) 4.4 (2.5) 0.109
CD20HLA 99.5 (0.4) 99.8 (0.2) 0.657
CD20CD25 25.6 (17.3) 19.3 (18.6) 0.309
CD20CD80 8.4 (4.7) 9.8 ( 9.1) 0.875
CD20CD86 13.4 (11.5) 22.4 (16.2) 0.071
CD3CD4 * 73.0 (5.9) 50.9 (19.0) 0.000
CD3CD8 * 25.7 (5.9) 45.0 (13.7) 0.000
CD3CD4/CD3CD8 * 3.1 (1.1) 1.3 ( 0.8) 0.000
CD3TCRαβ * 97.6 (1.8) 93.0 ( 5.4) 0.009
CD3TCRγδ * 2.9 (1.7) 8.5 ( 5.3) 0.001
CD3CD45RA * 32.1 (15.6) 58.8 (11.7) 0.000
CD3CD45RO * 73.2 (11.6) 62.5 (10.4) 0.001
CD3HLA 19.7 (10.0) 22.0 (10.0) 0.554
CD3CD25 22.7 (12.6) 27.2 (8.4) 0.153
CD3CD28 * 88.6 (15.1) 70.6 (12.5) 0.003
CD3CD80 1.5 (1.3) 1.0 (1.0) 0.133
CD3CD95 79.7 (14.1) 74.7 (16.4) 0.220
CD3CD95L 55.7 (41.0) 50.9 (34.7) 0.530
CD3CD152 1.6 (1.3) 1.3 (1.4) 0.277
Table 3 - Percentage (mean ± standard deviation) of leuko-
cyte subpopulations in peripheral blood and pleural fluid of 
patients with neoplastic pleural effusions (*p < 0.05)
Cells Pleural fluid Blood P
CD15 * 1.5 (1.5) 66.7 (8.2) 0.002
CD14 20.1 (17.0) 7.4 (2.2) 0.754
CD14CD86 99.5 (1.1) 95.2 (10.5) 0.237
Lymphocytes * 76.2 (17.4) 20.5 (7.1) 0.000
CD3 * 60.2 (18.9) 12.3 (5.1) 0.000
CD20 7.6 (7.2) 2.9 (2.3) 0.061
CD56 2.3 (1.5) 3.2 (1.7) 0.268
CD20HLA * 98.1 (4.4) 99.1 (1.8) 0.033
CD20CD25 * 23.2 (19.3) 6.9 (6.3) 0.006
CD20CD80 19.4 (24.9) 17.1 (30.3) 0.849
CD20CD86 8.2 (8.5) 15.2 (19.5) 0.237
CD3CD4 * 66.0 (22.0) 47.8 (13.4) 0.001
CD3CD8 32.9 (21.4) 44.8 (17.9) 0.119
CD3CD4/CD3CD8 * 3.6 (3.1) 1.4 (0.9) 0.039
CD3TCRαβ * 97.3 (2.1) 91.9 (7.8) 0.028
CD3TCRγδ 3.8 (1.5) 6.3 (5.4) 0.217
002CD3CD45RA * 29.5 (23.4) 53.2 (17.9) 0.002
CD3CD45RO * 72.7 (21.7) 56.0 (21.0) 0.002
CD3HLA 19.9 (13.5) 18.6 (12.9) 0.837
CD3CD25 * * 24.6 (14.6) 30.9 (15.6) 0.048
CD3CD28 80.5 (23.9) 72.0 (11.6) 0.166
CD3CD80 2.0 (1.7) 0.7 (0.6) 0.055
CD3CD95 78.6 (16.3) 79.3 (13.6) 0.905
CD3CD95L 19.5 (21.9) 16.2 (22.1) 0.713
CD3CD152 2.0 (1.2) 5.2 (12.2) 0.666641
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we observed a significant decrease in the percentage of CD4 
T lymphocytes in the disease groups (p = 0.001). Despite 
the reduced percentage of CD4 lymphocytes in patients 
with cancer, the T cells of these patients coexpressed 
some activation markers, such as CD25 and CD80. In the 
tuberculosis group, CD95L and CD152 were increased in 
addition to these T-cell activation markers. Coexpression of 
T-cell activation markers suggests that these lymphocytes 
underwent the first stages of antigen activation.
Determination of apoptosis
The apoptosis data are expressed as the percentage of 
positive mononuclear cells in the fluid and blood of patients 
with tuberculosis or cancer and in the blood of control 
subjects. Apoptotic cells in the pleural fluid were only 
observed in 6 (20.0%) of the 30 patients studied (5 with 
tuberculosis: 5/14; 35.7%, and one with cancer: 1/16; 6.2%). 
The percentage of apoptotic mononuclear cells ranged from 
0.2 to 32.9% in the pleural fluid and from 1.7 to 27.0% in the 
blood (Table 5); in the control group this percentage ranged 
from 0.2 to 7.9% (Table 6).
DISCUSSION
Tuberculosis and cancer are among the main causes 
of exudative pleural effusions. Although the effusions are 
predominantly lymphocytic in both cases, many studies 
have evaluated the subpopulations, activation state, and 
relationship with a peripheral blood cellular profile.3-5,18,19
Separate analysis of the pleural fluid showed that only 
CD3 and CD14 cell subpopulations quantitatively differed 
between tuberculosis and cancer. CD3 cells predominate in 
tuberculosis, whereas CD14 cells are more highly expressed 
in cancer. It should be emphasized that the increase in 
CD14-positive mononuclear cells in neoplastic effusions 
Table 4 - Percentage (mean ± standard deviation) of leukocyte subpopulations in peripheral blood of patients with tuberculous and neoplastic pleural 
effusions as compared to the control group
Cells Malignant Tuberculous Control P
CD15  66.7 (8.2) 62.4 (8.1) 58.6 (13.9) 0.176
CD14 * 7.4 (2.2) 10.7 (3.0) 7.7 (3.4) 0.012 (2x1; 2x3)
CD14CD86 95.2 (10.6) 99.3 (0.5) 99.3 (0.5) 0.143
Lymphocytes  20.5 (7.1) 23.1 (6.8) 27.6 (9.6) 0.074
CD3 * 12.3 (5.1) 13.9 (4.6) 20.0 (9.4) 0.014 (3x1)
CD20 2.9 (2.3) 2.0 (1.1) 3.1 (1.6) 0.207
CD56 3.3 (1.7) 4.4 (2.5) 3.5 (1.6) 0.289
CD20HLA 99.1 (1.8) 99.8 (0.3) 99.8 (0.3) 0.411
CD20CD25 * 7.0 (6.3) 19.3 (18.6) 7.0 (2.9) 0.006 (2x1; 2x3)
CD20CD80 17.1 (30.4) 9.8 (9.1) 5.2 (4.6) 0.391
CD20CD86 * 15.2 (19.6) 22.4 (16.2) 8.5 (11.9) 0.004 (2x3)
CD3CD4 * 47.8 (13.4) 50.9 (14.0) 64.4 (8.0) 0.001 (3x1; 3x2)
CD3CD8 * 44.8 (17.8) 45.0 (13.7) 32.3 (7.3) 0.007 (2x3; 1x3)
CD3CD4/CD3CD8 * 1.4 (0.9) 1.3 (0.8) 2.1 (0.7) 0.008 (3x2; 3x1)
CD3TCRαβ 91.9 (7.8) 93.0 (5.4) 89.8 (19.1) 0.740
CD3TCRγδ * 6.3 (5.4) 8.4 (5.3) 4.7 (2.6) 0.049 (2x3)
002CD3CD45RA * 53.2 (17.9) 58.8 (11.8) 39.7 (11.9) 0.001 (2x3; 1x3)
CD3CD45RO 56.0 (21.0) 62.5 (10.3) 59.2 (13.7) 0.563
CD3HLA * 18.6 (12.9) 22.0 (10.0) 12.4 (6.0) 0.023 (2x3)
CD3CD25 * * 30.9 (15.6) 27.2 (8.5) 14.7 (4.9) 0.001 (1x3; 2x3)
CD3CD28 * 72.0 (11.6) 70.6 (2.5) 84.9 (7.7) 0.001 (3x2; 3x1)
CD3CD80 * 0.7 (0.6) 1.0 (0.9) 0.2 (0.2) 0.001 (2x3; 1x3)
CD3CD95 79.3 (13.6) 74.7 (16.5) 76.7 (9.6) 0.704
CD3CD95L * 16.2 (22.1) 50.9 (34.7) 13.2 (9.5) 0.005 (2x1; 2x3)
CD3CD152 * 5.2 (12.2) 1.3 (1.4) 0.5 (0.4) 0.022 (2x3)642
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been previously reported and is probably related to the 
predominance of this cell type over CD8-positive T cells 
or to reductions in the latter that have been observed in 
tuberculosis.8,9,12,15-18,26-29
The number of CD3CD45RO cells (activated memory T 
cells) was higher in the pleural fluid. This finding, together 
with the reduced CD3CD45RA population (naive T cells), 
suggests that this phenotype is related to the process of cell 
activation. No significant differences between fluid and 
blood were observed for other markers (CD95L, CD152, or 
HLA-DR).
Despite the importance of apoptosis in pathological 
processes, few investigations have been conducted on 
pleural effusions. In our study, the blood and fluid of only 
6 (20%) patients showed elevated percentages of apoptotic 
cells when compared to the blood of healthy subjects. Most 
(83.3%) samples with an elevated percentage of apoptotic 
cells were tuberculous exudates. To investigate the possible 
association between cells undergoing apoptosis and specific 
immunophenotypes, we evaluated the correlation of 
apoptosis with surface marker expression (CD14, CD3CD95, 
CD3CD95L, CD3CD28, CD3HLA-DR, CD3CD45RO, and 
CD3CD45RA), but no correlation could be established. 
However, cell apoptosis in these fluids might be related 
to signaling pathways that involve other molecules, such 
as Bcl-2 and Bax, or to a deficiency in phagocytotic 
mechanisms30,31. Further studies of pleural effusions are 
necessary to understand the pathophysiological mechanisms 
responsible for increased apoptosis.
The increased percentage of CD3CD95L cells in the 
blood of patients with tuberculosis as compared to controls 
Table 5 - Percentage of BrdUTP-positive mononuclear cells 
in pleural fluid and peripheral blood of patients with tuber-
culous (1–14) or neoplastic (15–30) pleural effusions
Patient Diagnosis Pleural fluid Blood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Tuberculosis
Malignant
 
 
30.27
32.88
0.93
0.57
0.47
0.70
30.25
1.26
0.64
0.70
29.86
1.30
20.64
0.32
1.10
0.83
0.36
0.74
0.92
3.05
0.62
0.53
0.70
0.76
0.76
0.23
0.62
1.91
23.58
0.73
26.66
1.75
---
---
---
---
6.45
---
---
---
15.27
---
---
---
---
---
---
---
---
1.89
---
---
---
---
---
---
---
---
8.06
---
Table 6 - Percentage of BrdUTP-positive mononuclear cells 
in the peripheral blood of healthy blood donors (control)
Control Blood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
3.62
-
-
5.94
5.72
3.86
5.60
7.92
0.74
1.02
4.46
4.32
2.94
2.74
1.68
0.20
0.20
3.98
7.90
2.86
was not associated with any change in this cell population in 
the peripheral blood. Previously, Gjomarkaj et al.25 studied 
mononuclear cells (CD14) derived from neoplastic effusions 
and showed that these cells coexpress the HLA-DR antigen 
(activation marker), produce interleukin 1β and tumor 
necrosis factor α (TNF α), and stimulate the proliferation of 
allogenic T lymphocytes. These findings suggest that these 
cells are involved in the tumor-associated inflammatory 
reaction.
Although the percentage of apoptotic T lymphocytes 
appeared to be higher in tuberculosis, the statistical 
significance of this difference was marginal. This result 
might be explained by the size of the sample (30 cases); 
however, the number of antigens analyzed and the 
complexity of preparations also limited the analysis.
As the pleural cavity represents a separate compartment, 
it is important to establish the relationship between local 
phenomena and systemic repercussions. When we compared 
the cellular composition of pleural fluid and blood, we 
observed a relative increase in CD4-positive T lymphocytes 
in the pleural fluid from patients with tuberculosis and 
patients with cancer (higher in tuberculosis). This increase 
of CD4-positive T lymphocytes in the pleural fluid has 643
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and patients with cancer might reflect the host response to 
mycobacterial infection. These bacteria escape destruction 
by macrophages by preventing the fusion of phagosomes 
and lysosomes, thereby impairing the bactericidal action 
of lysosomal components.32,33 Organisms use multiple 
mechanisms to prevent mycobacterial infection, such as 
the activation of a Th1-type response. Once activated, these 
lymphocytes express Fas ligand (CD95L) on their membrane 
to eliminate a variety of cells, including macrophages, that 
express the Fas molecule (CD95), resulting in the destruction 
of cells infected with mycobacteria.31 Our finding of 
CD95L expression by lymphocytes might be related to this 
mechanism.
In the present study, we have evaluated various 
cellular apoptosis markers to characterize the cellular 
phenotypes of patients with tuberculous or neoplastic pleural 
effusions. In addition, we used the total cell content of the 
pleural fluid in our evaluations. This approach minimizes 
sample manipulation and reduces the loss of leukocyte 
subpopulations. 
CONCLUSION
Tuberculous and malignant pleural effusions are enriched 
in lymphocytes with a helper/inducer T cell phenotype, 
which are mainly memory cells. CD14-positive cells 
were more prevalent in malignant effusions, while CD3-
positive cells expressing Fas ligand were more prevalent in 
tuberculous effusions.
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